Annual report pursuant to Section 13 and 15(d)

Merger, Contingent Value Rights Agreement (Details)

v3.22.1
Merger, Contingent Value Rights Agreement (Details)
12 Months Ended
Dec. 31, 2021
USD ($)
Milestone
Nov. 05, 2020
Right
Milestone
Contingent Value Rights Agreement [Abstract]    
Contingent value rights payment period 15 years  
Sum of cash consideration paid by a third party   75.00%
Parent IP deal period 10 years  
Payments due under CVR Agreement | $ $ 91,000  
Number of milestones accrued 0 0
Number of potential milestones 0 0
Rexahn [Member]    
Contingent Value Rights Agreement [Abstract]    
Number of contingent value right received per common stock | Right   1
Rexahn [Member] | BioSense Global LLC [Member]    
Contingent Value Rights Agreement [Abstract]    
Percentage of payments received by Rexahn or its affiliates   90.00%
Rexahn [Member] | Zhejiang HaiChang Biotechnology Co., Ltd [Member]    
Contingent Value Rights Agreement [Abstract]    
Percentage of payments received by Rexahn or its affiliates   90.00%